Your browser is no longer supported. Please, upgrade your browser.
MESO Mesoblast Limited daily Stock Chart
Mesoblast Limited
Index- P/E- EPS (ttm)-0.74 Insider Own- Shs Outstand105.76M Perf Week11.92%
Market Cap2.27B Forward P/E- EPS next Y-0.01 Insider Trans- Shs Float101.89M Perf Month4.63%
Income-77.90M PEG- EPS next Q-0.23 Inst Own2.50% Short Float2.61% Perf Quarter73.42%
Sales32.20M P/S70.56 EPS this Y18.90% Inst Trans17.30% Short Ratio2.45 Perf Half Y428.26%
Book/sh5.19 P/B3.75 EPS next Y98.20% ROA-11.40% Target Price21.60 Perf Year186.73%
Cash/sh1.11 P/C17.58 EPS next 5Y48.80% ROE-15.50% 52W Range3.12 - 21.28 Perf YTD163.77%
Dividend- P/FCF- EPS past 5Y13.10% ROI-9.80% 52W High-11.70% Beta3.55
Dividend %- Quick Ratio1.50 Sales past 5Y10.20% Gross Margin21.30% 52W Low502.22% ATR0.96
Employees102 Current Ratio1.50 Sales Q/Q-65.00% Oper. Margin- RSI (14)57.75 Volatility4.17% 5.10%
OptionableYes Debt/Eq0.18 EPS Q/Q-48.50% Profit Margin- Rel Volume1.05 Prev Close19.44
ShortableYes LT Debt/Eq0.12 EarningsAug 26 AMC Payout- Avg Volume1.09M Price18.79
Recom1.80 SMA206.50% SMA5015.39% SMA20071.68% Volume115,261 Change-3.34%
Aug-14-20Reiterated Maxim Group Buy $16 → $22
May-28-20Reiterated H.C. Wainwright Buy $14 → $21
Jan-31-19Resumed H.C. Wainwright Buy $6.50
Mar-22-18Downgrade Credit Suisse Neutral → Underperform
Feb-28-18Reiterated Cantor Fitzgerald Buy $20 → $23
Aug-31-17Initiated Oppenheimer Outperform $16
Jun-08-17Initiated Cantor Fitzgerald Buy
Sep-17-20 10:11AM  
Sep-15-20 06:00AM  
Sep-10-20 09:04AM  
Sep-04-20 06:00AM  
Sep-02-20 06:00AM  
Aug-26-20 07:45PM  
Aug-25-20 08:37PM  
Aug-19-20 08:00AM  
Aug-18-20 05:30PM  
Aug-17-20 04:00PM  
Aug-16-20 09:55PM  
Aug-14-20 04:22PM  
Aug-13-20 09:57PM  
Aug-12-20 07:51AM  
Aug-11-20 02:46PM  
Jul-21-20 05:33PM  
Jul-16-20 09:32PM  
Jul-10-20 12:18PM  
Jul-06-20 04:37PM  
Jun-01-20 06:00AM  
May-30-20 10:49PM  
May-28-20 11:00AM  
May-27-20 05:53PM  
May-26-20 06:00AM  
May-25-20 07:00AM  
May-19-20 08:03PM  
May-13-20 02:23PM  
May-06-20 06:00AM  
Apr-30-20 07:00AM  
Apr-27-20 06:25PM  
Apr-24-20 06:00AM  
Apr-17-20 06:00AM  
Apr-15-20 08:35AM  
Apr-13-20 07:46PM  
Apr-10-20 11:38AM  
Apr-08-20 07:15PM  
Apr-06-20 06:00AM  
Apr-03-20 02:42AM  
Apr-01-20 06:00AM  
Mar-30-20 06:00AM  
Mar-11-20 11:06AM  
Mar-10-20 06:00AM  
Feb-28-20 07:35PM  
Feb-26-20 04:59PM  
Feb-25-20 06:00AM  
Feb-24-20 06:00AM  
Feb-20-20 06:00AM  
Feb-03-20 06:00AM  
Jan-23-20 03:26PM  
Jan-20-20 09:59AM  
Jan-17-20 09:22AM  
Jan-15-20 06:00AM  
Jan-09-20 08:46AM  
Jan-08-20 07:24AM  
Jan-03-20 07:19AM  
Jan-02-20 06:00AM  
Jan-01-20 05:45PM  
Dec-18-19 06:00AM  
Dec-17-19 06:00AM  
Dec-09-19 03:24PM  
Nov-29-19 03:26PM  
Nov-25-19 04:52PM  
Nov-21-19 04:29PM  
Oct-16-19 06:17PM  
Oct-08-19 08:10AM  
Oct-03-19 07:59AM  
Sep-25-19 09:13AM  
Sep-23-19 06:00AM  
Sep-09-19 07:40PM  
Aug-29-19 05:50PM  
Aug-27-19 06:36PM  
Aug-14-19 06:00AM  
Aug-12-19 06:00AM  
Jul-31-19 06:00AM  
Jul-27-19 08:50PM  
Jul-25-19 06:00AM  
Jun-28-19 12:40AM  
Jun-25-19 04:32PM  
Jun-24-19 02:16PM  
Jun-18-19 06:00AM  
Jun-14-19 10:28AM  
Jun-11-19 06:00AM  
May-30-19 07:09PM  
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grunenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.